Literature DB >> 32449438

Sevoflurane attenuates cardiomyocyte apoptosis by mediating the miR-219a/AIM2/TLR4/MyD88 axis in myocardial ischemia/reperfusion injury in mice.

Yan Li1, Na Xing1, Jingjing Yuan1, Jianjun Yang1.   

Abstract

Myocardial infarction (MI) is a vital cause of death and disability globally. The primary treatment for diminishing acute myocardial ischemic injury is myocardial reperfusion, which may induce cardiomyocyte death. Our aim is to unravel the mechanism of sevoflurane (Sev) in microRNA-219a (miR-219a)-mediated regulation of absent in melanoma 2 (AIM2) and TLR4/MyD88 pathway during myocardial ischemia/reperfusion (I/R). The area of MI and apoptosis of cardiomyocytes of the developed mouse model were evaluated by TTC staining and TUNEL, respectively. After the determination of miR-219a as our target using microarray analysis, miR-219a atagomiR was used to treat the mouse model. The luciferase assay verified whether miR-219a targeted AIM2, and the miR-219a and AIM2 expression in myocardial tissues was detected by RT-qPCR and Western blot. miR-219a was significantly increased in myocardial tissues from mice treated with Sev, and the area of MI and cardiomyocyte apoptosis were decreased as a consequence. The miR-219a inhibitor reversed the action of Sev. Moreover, overexpression of AIM2 or induction of the TLR4 pathway aggravated myocardial I/R injury alleviated by miR-219a. All in all, the treatment of Sev upregulated miR-219a expression, which blocked the TLR4 pathway by targeting AIM2 and attenuated cardiomyocyte apoptosis in myocardial I/R mouse model.

Entities:  

Keywords:  AIM2; Sevoflurane; TLR4/MyD88 pathway; microRNA-219a; myocardial ischemia/reperfusion

Year:  2020        PMID: 32449438      PMCID: PMC7469529          DOI: 10.1080/15384101.2020.1765512

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  33 in total

Review 1.  Myocardial ischemia reperfusion injury: from basic science to clinical bedside.

Authors:  Anja Frank; Megan Bonney; Stephanie Bonney; Lindsay Weitzel; Michael Koeppen; Tobias Eckle
Journal:  Semin Cardiothorac Vasc Anesth       Date:  2012-02-23

2.  AIM2 gene silencing attenuates diabetic cardiomyopathy in type 2 diabetic rat model.

Authors:  Xuyang Wang; Jinyu Pan; Hui Liu; Mingjun Zhang; Dian Liu; Lu Lu; Jingjing Tian; Ming Liu; Tao Jin; Fengshuang An
Journal:  Life Sci       Date:  2019-02-18       Impact factor: 5.037

3.  Activation of NLRP3 and AIM2 inflammasomes in Kupffer cells in hepatic ischemia/reperfusion.

Authors:  Hyo-Yeon Kim; Seok-Joo Kim; Sun-Mee Lee
Journal:  FEBS J       Date:  2014-11-14       Impact factor: 5.542

4.  Sevoflurane preconditioning attenuates myocardial ischemia/reperfusion injury via caveolin-3-dependent cyclooxygenase-2 inhibition.

Authors:  Jianli Zhao; Feng Wang; Yanqing Zhang; Liyuan Jiao; Wayne Bond Lau; Lili Wang; Baojiang Liu; Erhe Gao; Walter J Koch; Xin-Liang Ma; Yajing Wang
Journal:  Circulation       Date:  2013-09-10       Impact factor: 29.690

5.  miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway.

Authors:  Zhenhua Hu; Mingbo Cai; Ying Zhang; Lingling Tao; Ruixia Guo
Journal:  Cell Cycle       Date:  2019-12-29       Impact factor: 4.534

6.  Phosphorylation of the kinase interaction motif in mitogen-activated protein (MAP) kinase phosphatase-4 mediates cross-talk between protein kinase A and MAP kinase signaling pathways.

Authors:  Robin J Dickinson; Laurent Delavaine; Rocío Cejudo-Marín; Graeme Stewart; Christopher J Staples; Mark P Didmon; Antonio Garcia Trinidad; Andrés Alonso; Rafael Pulido; Stephen M Keyse
Journal:  J Biol Chem       Date:  2011-09-09       Impact factor: 5.157

7.  Inflammasome and toll-like receptor signaling in human monocytes after successful cardiopulmonary resuscitation.

Authors:  Alexander Asmussen; Katrin Fink; Hans-Jörg Busch; Thomas Helbing; Natascha Bourgeois; Christoph Bode; Sebastian Grundmann
Journal:  Crit Care       Date:  2016-06-04       Impact factor: 9.097

8.  Protocatechuic Acid-Mediated miR-219a-5p Activation Inhibits the p66shc Oxidant Pathway to Alleviate Alcoholic Liver Injury.

Authors:  Rong Fu; Junjun Zhou; Ruiwen Wang; Ruimin Sun; Dongcheng Feng; Zhecheng Wang; Yan Zhao; Li Lv; Xiaofeng Tian; Jihong Yao
Journal:  Oxid Med Cell Longev       Date:  2019-07-24       Impact factor: 6.543

9.  HMGB1 participates in LPS‑induced acute lung injury by activating the AIM2 inflammasome in macrophages and inducing polarization of M1 macrophages via TLR2, TLR4, and RAGE/NF‑κB signaling pathways.

Authors:  Jing Wang; Ruiting Li; Zhiyong Peng; Bo Hu; Xin Rao; Jianguo Li
Journal:  Int J Mol Med       Date:  2019-11-12       Impact factor: 4.101

10.  Shenlian Extract Against Myocardial Injury Induced by Ischemia Through the Regulation of NF-κB/IκB Signaling Axis.

Authors:  Yuan Guo; Qing Yang; Xiao-Gang Weng; Ya-Jie Wang; Xue-Qi Hu; Xiao-Jun Zheng; Yu-Jie Li; Xiao-Xin Zhu
Journal:  Front Pharmacol       Date:  2020-03-06       Impact factor: 5.810

View more
  4 in total

1.  Ibuprofen Alleviates Acute Pancreatitis- (AP-) Induced Myocardial Injury by Inhibiting AIM2.

Authors:  Ke Chen; Shaohua Wang
Journal:  Comput Math Methods Med       Date:  2022-07-08       Impact factor: 2.809

2.  The Association of Serum AIM2 Level with the Prediction and Short-Term Prognosis of Coronary Artery Disease.

Authors:  Wenkang Zhang; Gaoliang Yan; Chunyang Xu; Chengchun Tang
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2022-05-14       Impact factor: 4.109

Review 3.  Emerging Roles of Inflammasomes in Cardiovascular Diseases.

Authors:  Yingnan Liao; Kui Liu; Liyuan Zhu
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

4.  Mesenchymal Stem Cell Exosomal miR-146a Mediates the Regulation of the TLR4/MyD88/NF-κB Signaling Pathway in Inflammation due to Diabetic Retinopathy.

Authors:  Cao Gu; Hongjun Zhang; Shaofei Zhao; Daotong He; Yu Gao
Journal:  Comput Math Methods Med       Date:  2022-06-18       Impact factor: 2.809

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.